# Novel Dose Adjustment Schedule for Late Injection in SCIT in AR

> **NCT04929093** · PHASE4 · COMPLETED · sponsor: **Beijing Tongren Hospital** · enrollment: 102 (actual)

## Conditions studied

- Allergic Rhinitis
- Immunotherapy

## Interventions

- **BIOLOGICAL:** Novel dose adjustment of Alutard SQ
- **BIOLOGICAL:** conventional dose adjustment of Alutard SQ
- **BIOLOGICAL:** Routine continuous cluster of Alutard SQ

## Key facts

- **NCT ID:** NCT04929093
- **Lead sponsor:** Beijing Tongren Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-11
- **Primary completion:** 2021-04-16
- **Final completion:** 2021-04-30
- **Target enrollment:** 102 (ACTUAL)
- **Last updated:** 2021-06-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04929093

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04929093, "Novel Dose Adjustment Schedule for Late Injection in SCIT in AR". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04929093. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*